Correspondence 0001493152-24-011492 from FibroBiologics, Inc. (FBLG)

FibroBiologics, Inc.
Date: March 27, 2024 · CIK: 0001958777 · Accession: 0001493152-24-011492

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-277019

Date

March 27, 2024

Author

FibroBiologics

Form

CORRESP

Company

FibroBiologics, Inc.

Letter

VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Jimmy (CF) McNamara Laura Crotty RE: FibroBiologics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-277019

Dear Mr. McNamara and Ms. Crotty:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-277019) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on March 28, 2024, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time.

We request that we be notified of such effectiveness by a telephone call to Brian Fenske at (713) 651-5557 or Lee McIntyre at (713) 651-5328 of Norton Rose Fulbright (US) LLP, and that such effectiveness also be confirmed in writing.

Very
truly yours,
FibroBiologics,
Inc.

Show Raw Text

CORRESP
1
filename1.htm

FIBROBIOLOGICS,
INC.

455
E. Medical Center Blvd.

Suite
300

Houston,
Texas 77598

March
27, 2024

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

100
F Street, N.E.

Washington,
D.C. 20549

    Attention:
    Jimmy
                                            (CF) McNamara

    Laura
    Crotty

    RE:
    FibroBiologics,
    Inc. (the “Company”)

    Registration
    Statement on Form S-1

    File
    No. 333-277019

Dear
Mr. McNamara and Ms. Crotty:

Pursuant
to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the
Company’s Registration Statement on Form S-1 (File No. 333-277019) be accelerated by the Securities and Exchange Commission to
4:00 p.m. Washington D.C. time on March 28, 2024, or as soon as practicable thereafter, unless the Company notifies you otherwise prior
to such time.

We
request that we be notified of such effectiveness by a telephone call to Brian Fenske at (713) 651-5557 or Lee McIntyre at (713) 651-5328
of Norton Rose Fulbright (US) LLP, and that such effectiveness also be confirmed in writing.

    Very
    truly yours,

    FibroBiologics,
    Inc.

    By:
    /s/
    Pete O’Heeron

    Name:
    Pete O’Heeron

    Title:

    Chief Executive Officer

SecProbe.io